Roche refreshingly cautious on Alzheimer's hopeful gantenerumab amid growing hype from rivals

As Eli Lilly and Biogen stir up hope in the Alzheimer’s disease drug space, Roche’s pharma CEO is not getting dragged into hype over its effort gantenerumab.

Roche is certainly committed to gantenerumab, an antibody that binds to and clears aggregated beta amyloid fibers, despite it failing a phase 3 trial back in 2014. The Swiss pharma resurrected gantenerumab in 2017 and is now running two more phase 3 trials, although it was hit by another setback last year.